ArticleSignal transduction and targeted therapy2026
Intracellular logic computing with DNA tetrahedron processors enables precision cancer theranostics.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The integration of molecular computation with nanomedicine holds transformative potential for precision cancer theranostics. However, achieving an intelligent, multi-input decision-making process within living cells remains a formidable challenge because of the complexity of intracellular signaling networks. Here, we present a set of DNA tetrahedron logic processors that enable smart intracellular computing through a programmable three-input architecture capable of executing seven Boolean operations-OR, AND, NOR, NAND, XOR, majority (MAJ), and OR-AND-in response to endogenous miRNA signals. Building upon the cell-internalizable tetrahedral framework nucleic acid, this processor functions as an autonomous sense-and-treat module: it decodes combinatorial biomarker states and conditionally releases therapeutic siRNA only when a predefined logical condition is met. As a proof of concept, in precision oncology, we engineered a MAJ-gated nanoplatform (siR@MAJ) that selectively silences survivin in MCF-7 breast cancer cells that exhibit a specific tri-miRNA signature while sparing other cell types. This approach has achieved potent tumor suppression both in vitro and in vivo with high specificity and minimal off-target effects. By integrating multi-target detection into a single logic circuit, this processor significantly improves the discriminative capability within complex biological environments. Our work establishes a foundational platform for intelligent intracellular diagnostics and therapy, paving the way toward adaptive, logic-driven nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.